Related references
Note: Only part of the references are listed.Systemic Therapy for Advanced Human 3 Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).
Erika P. Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer
Josee-Lyne Ethier et al.
JAMA ONCOLOGY (2021)
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics
Cameron M. Phillips et al.
CANCER (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group.
Mark S. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions
Kristin M. Sheffield et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma
Belinda A. Campbell et al.
CANCERS (2020)
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Sara A. Hurvitz et al.
CLINICAL CANCER RESEARCH (2019)
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
Christine M. Cramer-van der Welle et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
Darius N. Lakdawalla et al.
VALUE IN HEALTH (2017)
Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study
Gong Yue et al.
SCIENTIFIC REPORTS (2017)
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Stacy L. Moulder et al.
CLINICAL CANCER RESEARCH (2017)
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Hanna K. Sanoff et al.
ONCOLOGIST (2016)
The Efficacy-Effectiveness Gap: Historical Background and Current Conceptualization
Clementine Nordon et al.
VALUE IN HEALTH (2016)
EFFICACY-EFFECTIVENESS-GAP - EXTENT, CAUSES AND IMPLICATIONS
N. Amler et al.
VALUE IN HEALTH (2015)
Efficacy vs. effectiveness: Erlotinib in previously treated non-small-cell lung cancer
Naureen Sheikh et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2012)
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
Adam M. Brufsky et al.
CLINICAL CANCER RESEARCH (2011)
Share Paper
